{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kavunja HW"],"funding":["National Cancer Institute (US)","NCI NIH HHS"],"pagination":["451-460"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5470645"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["66(4)"],"pubmed_abstract":["Cytotoxic T lymphocyte (CTL) can have remarkable abilities to kill tumor cells. However, the establishment of successful CTL-based anticancer therapy has met with many challenges. Within tumor cells, there exist subpopulations with low or no expression of the targeted antigen (termed as antigen-loss variants). In addition, tumor cells can downregulate the levels of major histocompatibility complex class I (MHC-I) molecules on cell surface due to immune pressure. As a result, some tumor cells can escape the immune pressure bestowed by CTLs, resulting in treatment failure. To address these difficulties, a new approach is developed to deliver foreign high-affinity CTL epitopes to tumor tissues utilizing pH-responsive \"smart\" microparticles (MPs). These MPs could encapsulate CTL peptide epitop"],"journal":["Cancer immunology, immunotherapy : CII"],"pubmed_title":["Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice."],"pmcid":["PMC5470645"],"funding_grant_id":["R01CA149451","R01 CA149451"],"pubmed_authors":["Kavunja HW","Huang X","Lang S","Sungsuwan S","Yin Z"],"additional_accession":[]},"is_claimable":false,"name":"Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice.","description":"Cytotoxic T lymphocyte (CTL) can have remarkable abilities to kill tumor cells. However, the establishment of successful CTL-based anticancer therapy has met with many challenges. Within tumor cells, there exist subpopulations with low or no expression of the targeted antigen (termed as antigen-loss variants). In addition, tumor cells can downregulate the levels of major histocompatibility complex class I (MHC-I) molecules on cell surface due to immune pressure. As a result, some tumor cells can escape the immune pressure bestowed by CTLs, resulting in treatment failure. To address these difficulties, a new approach is developed to deliver foreign high-affinity CTL epitopes to tumor tissues utilizing pH-responsive \"smart\" microparticles (MPs). These MPs could encapsulate CTL peptide epitop","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Apr","modification":"2025-04-19T17:33:47.24Z","creation":"2025-04-19T17:33:47.24Z"},"accession":"S-EPMC5470645","cross_references":{"pubmed":["28011995"],"doi":["10.1007/s00262-016-1948-9"]}}